Steve Schonfeld’s Celldex Therapeutics CLDX Stock Holding History

Steve Schonfeld’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-118,775	Closed	-$2.42M	–	2247
2025 Q2	$2.42M	Buy	+118,775	New	+$2.31M	0.02%	882
2024 Q3	–	Sell	-119,629	Closed	-$4.43M	–	2085
2024 Q2	$4.43M	Buy	+119,629	New	+$4.51M	0.03%	591
2024 Q1	–	Sell	-130,542	Closed	-$5.18M	–	2103
2023 Q4	$5.18M	Buy	+130,542	New	+$3.84M	0.03%	507
2023 Q1	–	Sell	-14,266	Closed	-$636K	–	2164
2022 Q4	$636K	Buy	+14,266	New	+$509K	0.01%	1397
2022 Q2	–	Sell	-14,100	Closed	-$481K	–	2595
2022 Q1	$481K	Buy	14,100 +457	+3%	+$14.6K	﹤0.01%	1399
2021 Q4	$527K	Sell	13,643 -43,164	-76%	-$1.88M	﹤0.01%	1235
2021 Q3	$3.07M	Sell	56,807 -20,073	-26%	-$942K	0.03%	570
2021 Q2	$2.57M	Buy	76,880 +42,310	+122%	+$1.16M	0.03%	636
2021 Q1	$712K	Buy	+34,570	New	+$794K	0.01%	1020

Other funds holding CLDX

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Steve Schonfeld's CLDX Position: Q3 2025 in Review

Steve Schonfeld sold out of Celldex Therapeutics (CLDX) in Q3 2025, closing a stake of 118,775 shares — an estimated $2.42M sold.

Steve Schonfeld first reported a position in CLDX in Q1 2021 and held it in 9 quarters. The position peaked at $5.18M in Q4 2023. 184 funds tracked by Wall St. Rank hold CLDX as of Q3 2025.

Steve Schonfeld reported no remaining Celldex Therapeutics position as of Q3 2025 after selling out during the quarter.
Steve Schonfeld sold 118,775 Celldex Therapeutics shares in Q3 2025, an estimated $2.42M.
Steve Schonfeld first reported a position in Celldex Therapeutics in Q1 2021 and held it in 9 quarters.
Steve Schonfeld's Celldex Therapeutics position peaked at $5.18M in Q4 2023.
184 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.